Guosheng Securities' research report points out that APT Medical Inc. (688617.SH) PFA products combine three major special features, demonstrating good safety and effectiveness. The company's innovative PFA product is the world's first ablation system that integrates 'pressure perception/attachment indication' + 'magnetoelectric positioning 3D measurement' + 'pulse ablation', possessing a unique technological advantage. Approval of the company's PFA products enriches the product layout in the electrophysiology field, and there is bullish sentiment regarding Mindray's involvement in continuously empowering the company's R&D and sales both domestically and internationally. The share of China's atrial fibrillation pulsed electric field ablation devices in cardiac electrophysiology devices will continue to increase, expected to rise from 8.18% in 2025 to 38.87% in 2032. Furthermore, the acceleration of project approvals the company is researching marks the gradual formation of a platform company. Maintaining a 'Buy' rating.